Provided By GlobeNewswire
Last update: May 8, 2025
Topline data from multiple Phase 2 studies expected throughout 2025
• Q2 readout from VTX3232 study in patients with early Parkinson’s disease
VENTYX BIOSCIENCES INC
NASDAQ:VTYX (9/26/2025, 8:00:02 PM)
2.98
+0.29 (+10.78%)
Find more stocks in the Stock Screener